id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-D-1856-0161,FDA,FDA-2014-D-1856,Testimony from Paul Cederna (PSF),Other,Testimony,2016-10-19T04:00:00Z,2016,10,2016-10-19T04:00:00Z,,2016-10-19T21:02:50Z,,0,0,0900006482278d7b
FDA-2014-D-1856-0159,FDA,FDA-2014-D-1856,Testimony from Scot Glasberg,Other,Testimony,2016-10-19T04:00:00Z,2016,10,2016-10-19T04:00:00Z,,2016-10-19T20:36:21Z,,0,0,0900006482278d79
FDA-2014-D-1856-0153,FDA,FDA-2014-D-1856,Testimony from Rebecca Baergen (Alston & Bird LLP),Other,Testimony,2016-10-19T04:00:00Z,2016,10,2016-10-19T04:00:00Z,,2016-10-19T20:26:05Z,,0,0,0900006482277bdf
FDA-2014-D-1856-0160,FDA,FDA-2014-D-1856,Testimony from Peter Rubin (ASPS),Other,Testimony,2016-10-19T04:00:00Z,2016,10,2016-10-19T04:00:00Z,,2016-10-19T21:01:36Z,,0,0,090000648227896a
FDA-2014-D-1856-0087,FDA,FDA-2014-D-1856,Write-In Campaign #2 (Multiple Submitters 13) Form Letter Comment,Other,Form Letter,2016-04-27T04:00:00Z,2016,4,2016-04-27T04:00:00Z,,2016-04-27T14:01:02Z,,0,0,0900006481f67919
FDA-2014-D-1856-0086,FDA,FDA-2014-D-1856,"Draft Guidances Relating to the Regulation of Human Cells, Tissues,
and Cellular and Tissue-Based Products; Extension of Comment Periods",Proposed Rule,Extension of Comment Period,2016-04-22T04:00:00Z,2016,4,2016-04-22T04:00:00Z,2016-09-28T03:59:59Z,2016-10-20T01:00:57Z,2016-09366,0,0,0900006481f83c8e
FDA-2014-D-1856-0083,FDA,FDA-2014-D-1856,Write-In Campaign #1 (Multiple Submitters 17) Form Letter Comment,Other,Form Letter,2016-04-13T04:00:00Z,2016,4,2015-10-30T04:00:00Z,2016-04-30T03:59:59Z,2016-04-13T19:47:11Z,,0,0,0900006481f2eef7